Navigation Links
Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
Date:6/11/2008

ST. LOUIS, June 11 /PRNewswire/ -- Orion Genomics announced today that the company entered into a worldwide exclusive license agreement with The Johns Hopkins University (JHU) to commercialize products that identify patients at risk for colorectal cancer. The license is based on a suite of issued and pending JHU patents covering imprinting abnormalities of the insulin-like growth factor 2 gene (IGF2). Orion's simple blood-based risk assessment test is being designed to identify people who carry the IGF2 biomarker and may be at increased risk of developing sporadic colorectal cancer. It is expected that the test will enable at-risk patients to undergo screening for colorectal cancer significantly earlier, allowing physicians to remove precancerous polyps and prevent future colon cancer.

Two published studies involving more than 200 patients have found that colorectal cancer and adenoma patients are at least five times more likely to carry the IGF2 biomarker than age-matched cancer-free patients serving as controls.

"We are pleased to obtain this exclusive license from The Johns Hopkins University to complete the development of our lead cancer risk assessment product and enter the market in the near future," said Nathan D. Lakey, President and CEO of Orion Genomics. "Our colorectal cancer risk test has the potential to save lives by identifying a group of high risk individuals who are likely to develop colorectal cancer at a younger age, and who should undergo colonoscopy screening 10 to 20 years earlier than the age that is currently recommended."

Loss of imprinting of IGF2 is a non-heritable epigenetic mutation detected in the blood of seven to 10 percent of the general population. Although epigenetic mutations do not affect the DNA sequence of a gene, cancer associated epigenetic changes can either turn off or "silence" genes that normally suppress cancer, or can inappropriately turn on genes that can lead to malignant cellular activity.
'/>"/>

SOURCE Orion Genomics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
2. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
3. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
5. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
6. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
10. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...re/ -- New research has found that the availabilit...T) scanner in an emergency room can significantly ...a potentially life-saving treatment. Results of th...NSMC)-Salem Hospital in Salem, Mass., will be pres...cal Society of North America (RSNA). , , "T...
(Date:12/1/2008)...RNewswire-USNewswire/ -- A study has found that po... for imaging the breast, is not affected by either...factors that limit the effectiveness of standard m...ll be presented today at the annual meeting of the... , "The ability of PEM to detect cancer does...
(Date:12/1/2008)...irstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: ...f the world,s leading medical journals, results of... experimental compound tasimelteon (VEC-162). The...elatonin agonist tasimelteon (VEC-162) for transie... controlled multicentre trials." Results are repor...
(Date:12/1/2008)...rgeGen has announced that an oral,presentation of...d clinical,trial of TG101348 in myeloproliferativ... American Society of Hematology (ASH) Meeting. , ...:, Title: A Phase I Study of TG... JAK2-Selective Inhibitor, in Patients with,...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Helix BioPharma Announces 2411 4 Million Private Placement 7982 1Helix BioPharma Announces 2411 4 Million Private Placement 7982 2New England Peptide Names Director of Chemical Development 7977 1New England Peptide Names Director of Chemical Development 7977 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 1LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 3Kazak apple research key to preventing blue mold 5127 1Kazak apple research key to preventing blue mold 5127 2
...al Meeting of the American,Psychiatric Association... -- In adults with,major depressive disorder, addi...sulted in significant improvement in the primary,e...Scale (MADRS),Total Score. In this six-week, rando...the 160th Annual Meeting of the American,Psychiatr...
...ewswire/ -- Sirion Therapeutics,Inc., an ophthalm...day that it has received orphan drug designation f... anti-viral therapy,ganciclovir, for the treatmen...ently marketed by Laboratoires Thea in Europe unde... rights to,Virgan(R) for the United States from La...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2
(Date:12/2/2008)... At this year,s ASHP midyear meeting...rusted distributor of critical-care biopharmaceuti...model for supply chain integrity and demonstrate h...on to a new level. (Booth #1439) , ...,s ASHP midyear meeting, FFF Enterprises, the nati...
(Date:12/2/2008)... Marathon Health, a leading provider...s, has announced that New Balance, the athletic pr...velop, implement and manage onsite health clinics ...alance facilities in Maine , ...athon Health, a leading provider of onsite employe...
(Date:12/2/2008)... Does your over-the-phone interpreta... after you have completed the call? , ...2008 -- In the world of over-the-phone interpretat...OPI, a second over one minute can add up over the ...ding. When an organization employs an over-the-pho...
(Date:12/2/2008)... For many families, the problem with... Koch provides insight into how caregivers of agin...to the elder care experience. , ...or many families the stress of the holiday season ...t and elder care expert Esther Koch , founder of ...
Breaking Medicine News(10 mins):Health News:FFF Enterprises Unveils ‘The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 2Health News:FFF Enterprises Unveils ‘The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 3Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 2Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3
...troke victims to bust blood clots may help treat s... according to a study published Monday. While tre... significantly in the last 25 years, it has largel...tbite, say the authors of the article published in...
...f an unarmed man on his wedding day, the New York ...halyzer tests after such shootings. Sean Bell, a 2... girlfriend, died in a hail of 50 bullets hours be...ar. Police opened fire on Bells car outside a top...
...on for cancer patients who have to spend weeks in ...ase of Nick Gall-Tomassen, aged 31, suffering fro...on time away from the ward. His backpack holds re...t into his body through a vein in his arm. Nick sa...
... Heart Center helps explain excessive body weight ...body weight is associated with a thickening of the...mping chamber. Known to physicians as left ventric...can lead to heart failure and rhythm problems. &#...
Other Medicine News:Health News:Frostbite can Be Treated by Bloodclot Drug 2Health News:Breathalyzer Tests for Cops Involved in Shootings 2Health News:Special Backpacks Provide Much Needed Relief for Cancer Patients 2
Avant E-Z Rack Premium Low Binding 10 l Microreach Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone.
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Medicine Products: